Company Description
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents.
OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Country | United States |
| Founded | 2009 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Joshua Riggs |
Contact Details
Address: 15 Cushing Irvine, California 92618 United States | |
| Phone | 949 409 7600 |
| Website | oncocyte.com |
Stock Details
| Ticker Symbol | OCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001642380 |
| CUSIP Number | 68235C107 |
| ISIN Number | US68235C2061 |
| Employer ID | 27-1041563 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael D. West Ph.D. | Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc. |
| Joshua Riggs | President, Chief Executive Officer and Director |
| James Liu | Senior Director, Controller and Principal Accounting Officer |
| Dr. Ekkehard Schutz M.D., Ph.D. | Chief Science Officer |
| Andrea Susan James | Chief Financial Officer |
| Yuh-Min Chiang Ph.D. | Chief Technology Officer |
| Peter Hong | Vice President, General Counsel and Secretary |
| Sandra O'Donald | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | 424B3 | Prospectus |
| Oct 21, 2024 | EFFECT | Notice of Effectiveness |
| Oct 18, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Oct 16, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 8, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 3, 2024 | 8-K | Current Report |
| Sep 25, 2024 | DEF 14A | Other definitive proxy statements |